Entry - #603147 - CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ic; CDG1C - OMIM
# 603147

CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ic; CDG1C


Alternative titles; symbols

CDG Ic; CDGIc
CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME, TYPE I, WITH DEFICIENT GLYCOSYLATION OF DOLICHOL-LINKED OLIGOSACCHARIDE, FORMERLY
CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME, TYPE V, FORMERLY; CDGS5, FORMERLY


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
1p31.3 Congenital disorder of glycosylation, type Ic 603147 AR 3 ALG6 604566
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal recessive
HEAD & NECK
Eyes
- Strabismus
NEUROLOGIC
Central Nervous System
- Axial hypotonia
- Psychomotor retardation
- Areflexia
- Seizures
- Ataxia
HEMATOLOGY
- Factor XI deficiency
LABORATORY ABNORMALITIES
- Elevated serum transaminases during infections
- Abnormal isoelectric focusing of serum transferrin (type 1 pattern)
- Dolichyl-P-Glc:Man(9)GlcNAc(2)-PP-dolichyl glucosyltransferase deficiency
- Decreased serum cholesterol
- Decreased factor XI
- Decreased antithrombin III
- Decreased protein C
MOLECULAR BASIS
- Caused by mutation in the ALG6 alpha-1,3-glucosyltransferase gene (ALG6, 604566.0001)
Congenital disorders of glycosylation, type I - PS212065 - 29 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.12 Congenital disorder of glycosylation, type Ir AR 3 614507 DDOST 602202
1p36.11 Retinitis pigmentosa 59 AR 3 613861 DHDDS 608172
1p36.11 ?Congenital disorder of glycosylation, type 1bb AR 3 613861 DHDDS 608172
1p31.3 Congenital disorder of glycosylation, type Ic AR 3 603147 ALG6 604566
1p31.3 Congenital disorder of glycosylation, type It AR 3 614921 PGM1 171900
1q22 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 15 AR 3 612937 DPM3 605951
3p23 Congenital disorder of glycosylation, type Ix AR 3 615597 STT3B 608605
3p21.1 Congenital disorder of glycosylation, type In AR 3 612015 RFT1 611908
3q27.1 Congenital disorder of glycosylation, type Id AR 3 601110 ALG3 608750
4q12 Congenital disorder of glycosylation, type Iq AR 3 612379 SRD5A3 611715
6q22.1 ?Congenital disorder of glycosylation, type 1aa AR 3 617082 NUS1 610463
9q22.33 Congenital disorder of glycosylation, type Ii AR 3 607906 ALG2 607905
9q34.11 Congenital disorder of glycosylation, type Iu AR 3 615042 DPM2 603564
9q34.11 Congenital disorder of glycosylation, type Im AR 3 610768 DOLK 610746
11q14.1 Congenital disorder of glycosylation, type Ih AR 3 608104 ALG8 608103
11q23.1 Congenital disorder of glycosylation, type Il AR 3 608776 ALG9 606941
11q23.3 Congenital disorder of glycosylation, type Ij AR 3 608093 DPAGT1 191350
11q24.2 Congenital disorder of glycosylation, type Iw, autosomal recessive AR 3 615596 STT3A 601134
12q24.31 Cutis laxa, autosomal recessive, type IIA AR 3 219200 ATP6V0A2 611716
13q14.3 Congenital disorder of glycosylation, type Ip AR 3 613661 ALG11 613666
15q24.1-q24.2 Congenital disorder of glycosylation, type Ib AR 3 602579 MPI 154550
16p13.3 Congenital disorder of glycosylation, type Ik AR 3 608540 ALG1 605907
16p13.2 Congenital disorder of glycosylation, type Ia AR 3 212065 PMM2 601785
17p13.1 Congenital disorder of glycosylation, type If AR 3 609180 MPDU1 604041
20q13.13 Congenital disorder of glycosylation, type Ie AR 3 608799 DPM1 603503
22q13.33 Congenital disorder of glycosylation, type Ig AR 3 607143 ALG12 607144
Xq21.1 Congenital disorder of glycosylation, type Icc XLR 3 301031 MAGT1 300715
Xq23 Developmental and epileptic encephalopathy 36 XL 3 300884 ALG13 300776
Xq28 Congenital disorder of glycosylation, type Iy XLR 3 300934 SSR4 300090

TEXT

A number sign (#) is used with this entry because congenital disorder of glycosylation type Ic (CDG Ic, CDG1C) is caused by homozygous or compound heterozygous mutation in the ALG6 gene (604566) on chromosome 1p31.


Description

Congenital disorders of glycosylation, previously called carbohydrate-deficient glycoprotein syndromes (CDGSs), are caused by defects in mannose addition during N-linked oligosaccharide assembly. CDGs can be divided into 2 types, depending on whether they impair lipid-linked oligosaccharide (LLO) assembly and transfer (CDG I), or affect trimming of the protein-bound oligosaccharide or the addition of sugars to it (CDG II) (Orlean, 2000).

CDG Ic is characterized by psychomotor retardation with delayed walking and speech, hypotonia, seizures, and sometimes protein-losing enteropathy. It is the second largest subtype of CDG (summary by Sun et al., 2005).

For a discussion of the classification of CDGs, see CDG1A (212065).

Freeze and Aebi (1999) reviewed CDG Ib (602579) and CDG Ic.


Clinical Features

Burda et al. (1998) reported 4 related patients from a consanguineous Dutch family with type I CDG. There were 3 girls and 1 boy, aged 3 to 7 years. The most striking feature of the patients was a neurologic involvement. Biochemical data showed a CDG type 1 serum sialotransferrin pattern but normal levels of PMM2 (601785) activity. The clinical symptomatology was mild compared to patients with CDG1A.

Korner et al. (1998) reported a 7-year-old girl who had been noted in her first year to have a convergent squint, recurrent edema of the upper eyelids, and recurrent infections. Muscular hypotonia, ataxia, and mental and motor developmental retardation were present at the age of 6 months. Beginning at the age of 11 months, seizures occurred during infections. Nerve conduction velocity was always normal. MRI at the age of 4 years showed a slight general atrophy of the cerebrum and cerebellum. She had atrophic retinal pigmentation, reduction of retinal vascularization, and hyperopia. Pathologic coagulation parameters and levels of coagulation factors were found. The parents were described as healthy and unrelated; the family history was said to be 'inconspicuous.'

Sun et al. (2005) reported a woman with CDG Ic. She had severe mental retardation, seizures, broad-based gait, dysmetria, and intention tremor. She also had unusual characteristics, including distal limb defects and endocrine disturbances with hyperandrogenism. She had menarche at age 15, but menses were irregular. She developed pronounced virilization with facial hair, male pattern baldness, and low voice. Abdominal CT scan suggested polycystic ovaries. Hormonal workup showed low FSH and LH and increased testosterone. Insulin and glucose levels, as well as brain MRI, were normal. Sun et al. (2005) noted that the hormonal imbalances in females with CDG may be due to reduced bioactivity and bioavailability of FSH.


Biochemical Features

Burda et al. (1998) found that fibroblasts from 4 patients with CDG1C showed a specific deficiency in the assembly of the dolichol-linked oligosaccharide. There was an impaired glycosylation of the oligosaccharide leading to accumulation of dolichylpyrophosphate-linked Man(9)GlcNAc(2). The hypoglycosylation of serum proteins in these patients was thought to be explained by the fact that nonglycosylated oligosaccharides are suboptimal substrates in the protein glycosylation process that is catalyzed by the oligosaccharyltransferase complex. This explains the reduced efficiency of N-linked protein glycosylation that was found in fibroblasts from these patients.

Korner et al. (1998) described a form of CDG, originally designated type V, which clinically resembled the classic type Ia. Biochemical studies showed a deficiency of the glycosyltransferase that transfers glucose from dolichyl phosphate glucose (Dol-P-Glc) onto the lipid-linked oligosaccharide Man(9)GlcNAc(2)-PP-Dol. The defect was leaky and allowed for a residual synthesis of glucosylated forms of LLOs, which are known to be the preferred substrate of oligosaccharyltransferase. The biochemical phenotype was characterized by an accumulation of nonglucosylated LLOs, a marked reduction of glucosylated LLOs, and incomplete utilization of N-glucosylation sites in nascent glycoproteins. The enzyme deficient in this case was referred to as dolichyl-P-Glc:Man(9)GlcNAc(2)-PP-dolichyl glucosyltransferase.


Inheritance

The transmission pattern of CDG1C in the patients reported by Imbach et al. (1999) was consistent with autosomal recessive inheritance.


Molecular Genetics

Imbach et al. (1999) showed that all 4 of the patients with CDG1C described by Burda et al. (1998) had the same homozygous ala333-to-val point mutation in the ALG6 gene (A333V; 604566.0001).

Imbach et al. (2000) identified 7 additional patients with CDG1C. Four patients were homozygous for the previously described A333V mutation, and haplotype analysis indicated a founder effect. The other 3 patients had a different mutation in the ALG6 gene (604566.0002; 604566.0003).

Westphal et al. (2000) identified compound heterozygosity for 2 pathogenic mutations in the ALG6 gene (604566.0003 and 604566.0004) in a patient with CDG1C.

Sun et al. (2005) identified compound heterozygous mutations in the ALG6 gene (604566.0005 and 604566.0006) in a woman with CDG1C.

Reclassified Variants

The Y131H variant reported by Miller et al. (2011) has been reclassified as a variant of unknown significance; see 604566.0007. Miller et al. (2011) identified a homozygous mutation in the ALG6 gene (Y131H; 604566.0007) in a woman with CDG.


REFERENCES

  1. Burda, P., Borsig, L., de Rijk-Andel, J., Wevers, R., Jaeken, J., Carchon, H., Berger, E. G., Aebi, M. A novel carbohydrate-deficient glycoprotein syndrome characterized by a deficiency in glucosylation of the dolichol-linked oligosaccharide. J. Clin. Invest. 102: 647-652, 1998. [PubMed: 9710431, related citations] [Full Text]

  2. Freeze, H. H., Aebi, M. Molecular basis of carbohydrate-deficient glycoprotein syndromes type I with normal phosphomannomutase activity. Biochim. Biophys. Acta 1455: 167-178, 1999. Note: Erratum: Biochim. Biophys. Acta 1500: 349 only, 2000. [PubMed: 10571010, related citations] [Full Text]

  3. Imbach, T., Burda, P., Kuhnert, P., Wevers, R. A., Aebi, M., Berger, E. G., Hennet, T. A mutation in the human ortholog of the Saccharomyces cerevisiae ALG6 gene causes carbohydrate-deficient glycoprotein syndrome type-Ic. Proc. Nat. Acad. Sci. 96: 6982-6987, 1999. [PubMed: 10359825, images, related citations] [Full Text]

  4. Imbach, T., Grunewald, S., Schenk, B., Burda, P., Schollen, E., Wevers, R. A., Jaeken, J., de Klerk, J. B. C., Berger, E. G., Matthijs, G., Aebi, M., Hennet, T. Multi-allelic origin of congenital disorder of glycosylation (CDG)-Ic. Hum. Genet. 106: 538-545, 2000. [PubMed: 10914684, related citations] [Full Text]

  5. Korner, C., Knauer, R., Holzbach, U., Hanefeld, F., Lehle, L., von Figura, K. Carbohydrate-deficient glycoprotein syndrome type V: deficiency of dolichyl-P-Glc:Man(9)GlcNAc(2)-PP-dolichyl glucosyltransferase. Proc. Nat. Acad. Sci. 95: 13200-13205, 1998. [PubMed: 9789065, images, related citations] [Full Text]

  6. Miller, B. S., Freeze, H. H., Hoffmann, G. F., Sarafoglou, K. Pubertal development in ALG6 deficiency (congenital disorder of glycosylation type Ic). Molec. Genet. Metab. 103: 101-103, 2011. [PubMed: 21334936, related citations] [Full Text]

  7. Orlean, P. Congenital disorders of glycosylation caused by defects in mannose addition during N-linked oligosaccharide assembly. J. Clin. Invest. 105: 131-132, 2000. [PubMed: 10642590, related citations] [Full Text]

  8. Sun, L., Eklund, E. A., Van Hove, J. L. K., Freeze, H. H., Thomas, J. A. Clinical and molecular characterization of the first adult congenital disorder of glycosylation (CDG) type Ic patient. Am. J. Med. Genet. 137A: 22-26, 2005. [PubMed: 16007612, related citations] [Full Text]

  9. Westphal, V., Schottstadt, C., Marquardt, T., Freeze, H. H. Analysis of multiple mutations in the hALG6 gene in a patient with congenital disorder of glycosylation Ic. Molec. Genet. Metab. 70: 219-223, 2000. [PubMed: 10924277, related citations] [Full Text]


Cassandra L. Kniffin - updated : 5/19/2011
Hudson H. Freeze - updated : 2/17/2000
Hudson H. Freeze - reviewed : 2/17/2000
Victor A. McKusick - updated : 2/10/2000
Creation Date:
Victor A. McKusick : 10/15/1998
alopez : 05/15/2024
carol : 12/14/2023
carol : 10/06/2022
carol : 01/02/2020
carol : 06/05/2018
carol : 03/27/2017
alopez : 08/07/2015
terry : 9/14/2012
wwang : 6/8/2011
ckniffin : 5/19/2011
carol : 6/27/2007
carol : 6/26/2007
ckniffin : 6/26/2007
ckniffin : 6/22/2007
terry : 7/6/2004
carol : 3/1/2000
carol : 2/18/2000
carol : 2/17/2000
carol : 2/17/2000
terry : 2/10/2000
carol : 10/15/1998

# 603147

CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ic; CDG1C


Alternative titles; symbols

CDG Ic; CDGIc
CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME, TYPE I, WITH DEFICIENT GLYCOSYLATION OF DOLICHOL-LINKED OLIGOSACCHARIDE, FORMERLY
CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME, TYPE V, FORMERLY; CDGS5, FORMERLY


SNOMEDCT: 709412006;   ORPHA: 79320;   DO: 0080555;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
1p31.3 Congenital disorder of glycosylation, type Ic 603147 Autosomal recessive 3 ALG6 604566

TEXT

A number sign (#) is used with this entry because congenital disorder of glycosylation type Ic (CDG Ic, CDG1C) is caused by homozygous or compound heterozygous mutation in the ALG6 gene (604566) on chromosome 1p31.


Description

Congenital disorders of glycosylation, previously called carbohydrate-deficient glycoprotein syndromes (CDGSs), are caused by defects in mannose addition during N-linked oligosaccharide assembly. CDGs can be divided into 2 types, depending on whether they impair lipid-linked oligosaccharide (LLO) assembly and transfer (CDG I), or affect trimming of the protein-bound oligosaccharide or the addition of sugars to it (CDG II) (Orlean, 2000).

CDG Ic is characterized by psychomotor retardation with delayed walking and speech, hypotonia, seizures, and sometimes protein-losing enteropathy. It is the second largest subtype of CDG (summary by Sun et al., 2005).

For a discussion of the classification of CDGs, see CDG1A (212065).

Freeze and Aebi (1999) reviewed CDG Ib (602579) and CDG Ic.


Clinical Features

Burda et al. (1998) reported 4 related patients from a consanguineous Dutch family with type I CDG. There were 3 girls and 1 boy, aged 3 to 7 years. The most striking feature of the patients was a neurologic involvement. Biochemical data showed a CDG type 1 serum sialotransferrin pattern but normal levels of PMM2 (601785) activity. The clinical symptomatology was mild compared to patients with CDG1A.

Korner et al. (1998) reported a 7-year-old girl who had been noted in her first year to have a convergent squint, recurrent edema of the upper eyelids, and recurrent infections. Muscular hypotonia, ataxia, and mental and motor developmental retardation were present at the age of 6 months. Beginning at the age of 11 months, seizures occurred during infections. Nerve conduction velocity was always normal. MRI at the age of 4 years showed a slight general atrophy of the cerebrum and cerebellum. She had atrophic retinal pigmentation, reduction of retinal vascularization, and hyperopia. Pathologic coagulation parameters and levels of coagulation factors were found. The parents were described as healthy and unrelated; the family history was said to be 'inconspicuous.'

Sun et al. (2005) reported a woman with CDG Ic. She had severe mental retardation, seizures, broad-based gait, dysmetria, and intention tremor. She also had unusual characteristics, including distal limb defects and endocrine disturbances with hyperandrogenism. She had menarche at age 15, but menses were irregular. She developed pronounced virilization with facial hair, male pattern baldness, and low voice. Abdominal CT scan suggested polycystic ovaries. Hormonal workup showed low FSH and LH and increased testosterone. Insulin and glucose levels, as well as brain MRI, were normal. Sun et al. (2005) noted that the hormonal imbalances in females with CDG may be due to reduced bioactivity and bioavailability of FSH.


Biochemical Features

Burda et al. (1998) found that fibroblasts from 4 patients with CDG1C showed a specific deficiency in the assembly of the dolichol-linked oligosaccharide. There was an impaired glycosylation of the oligosaccharide leading to accumulation of dolichylpyrophosphate-linked Man(9)GlcNAc(2). The hypoglycosylation of serum proteins in these patients was thought to be explained by the fact that nonglycosylated oligosaccharides are suboptimal substrates in the protein glycosylation process that is catalyzed by the oligosaccharyltransferase complex. This explains the reduced efficiency of N-linked protein glycosylation that was found in fibroblasts from these patients.

Korner et al. (1998) described a form of CDG, originally designated type V, which clinically resembled the classic type Ia. Biochemical studies showed a deficiency of the glycosyltransferase that transfers glucose from dolichyl phosphate glucose (Dol-P-Glc) onto the lipid-linked oligosaccharide Man(9)GlcNAc(2)-PP-Dol. The defect was leaky and allowed for a residual synthesis of glucosylated forms of LLOs, which are known to be the preferred substrate of oligosaccharyltransferase. The biochemical phenotype was characterized by an accumulation of nonglucosylated LLOs, a marked reduction of glucosylated LLOs, and incomplete utilization of N-glucosylation sites in nascent glycoproteins. The enzyme deficient in this case was referred to as dolichyl-P-Glc:Man(9)GlcNAc(2)-PP-dolichyl glucosyltransferase.


Inheritance

The transmission pattern of CDG1C in the patients reported by Imbach et al. (1999) was consistent with autosomal recessive inheritance.


Molecular Genetics

Imbach et al. (1999) showed that all 4 of the patients with CDG1C described by Burda et al. (1998) had the same homozygous ala333-to-val point mutation in the ALG6 gene (A333V; 604566.0001).

Imbach et al. (2000) identified 7 additional patients with CDG1C. Four patients were homozygous for the previously described A333V mutation, and haplotype analysis indicated a founder effect. The other 3 patients had a different mutation in the ALG6 gene (604566.0002; 604566.0003).

Westphal et al. (2000) identified compound heterozygosity for 2 pathogenic mutations in the ALG6 gene (604566.0003 and 604566.0004) in a patient with CDG1C.

Sun et al. (2005) identified compound heterozygous mutations in the ALG6 gene (604566.0005 and 604566.0006) in a woman with CDG1C.

Reclassified Variants

The Y131H variant reported by Miller et al. (2011) has been reclassified as a variant of unknown significance; see 604566.0007. Miller et al. (2011) identified a homozygous mutation in the ALG6 gene (Y131H; 604566.0007) in a woman with CDG.


REFERENCES

  1. Burda, P., Borsig, L., de Rijk-Andel, J., Wevers, R., Jaeken, J., Carchon, H., Berger, E. G., Aebi, M. A novel carbohydrate-deficient glycoprotein syndrome characterized by a deficiency in glucosylation of the dolichol-linked oligosaccharide. J. Clin. Invest. 102: 647-652, 1998. [PubMed: 9710431] [Full Text: https://doi.org/10.1172/JCI2266]

  2. Freeze, H. H., Aebi, M. Molecular basis of carbohydrate-deficient glycoprotein syndromes type I with normal phosphomannomutase activity. Biochim. Biophys. Acta 1455: 167-178, 1999. Note: Erratum: Biochim. Biophys. Acta 1500: 349 only, 2000. [PubMed: 10571010] [Full Text: https://doi.org/10.1016/s0925-4439(99)00072-1]

  3. Imbach, T., Burda, P., Kuhnert, P., Wevers, R. A., Aebi, M., Berger, E. G., Hennet, T. A mutation in the human ortholog of the Saccharomyces cerevisiae ALG6 gene causes carbohydrate-deficient glycoprotein syndrome type-Ic. Proc. Nat. Acad. Sci. 96: 6982-6987, 1999. [PubMed: 10359825] [Full Text: https://doi.org/10.1073/pnas.96.12.6982]

  4. Imbach, T., Grunewald, S., Schenk, B., Burda, P., Schollen, E., Wevers, R. A., Jaeken, J., de Klerk, J. B. C., Berger, E. G., Matthijs, G., Aebi, M., Hennet, T. Multi-allelic origin of congenital disorder of glycosylation (CDG)-Ic. Hum. Genet. 106: 538-545, 2000. [PubMed: 10914684] [Full Text: https://doi.org/10.1007/s004390000293]

  5. Korner, C., Knauer, R., Holzbach, U., Hanefeld, F., Lehle, L., von Figura, K. Carbohydrate-deficient glycoprotein syndrome type V: deficiency of dolichyl-P-Glc:Man(9)GlcNAc(2)-PP-dolichyl glucosyltransferase. Proc. Nat. Acad. Sci. 95: 13200-13205, 1998. [PubMed: 9789065] [Full Text: https://doi.org/10.1073/pnas.95.22.13200]

  6. Miller, B. S., Freeze, H. H., Hoffmann, G. F., Sarafoglou, K. Pubertal development in ALG6 deficiency (congenital disorder of glycosylation type Ic). Molec. Genet. Metab. 103: 101-103, 2011. [PubMed: 21334936] [Full Text: https://doi.org/10.1016/j.ymgme.2011.01.016]

  7. Orlean, P. Congenital disorders of glycosylation caused by defects in mannose addition during N-linked oligosaccharide assembly. J. Clin. Invest. 105: 131-132, 2000. [PubMed: 10642590] [Full Text: https://doi.org/10.1172/JCI9157]

  8. Sun, L., Eklund, E. A., Van Hove, J. L. K., Freeze, H. H., Thomas, J. A. Clinical and molecular characterization of the first adult congenital disorder of glycosylation (CDG) type Ic patient. Am. J. Med. Genet. 137A: 22-26, 2005. [PubMed: 16007612] [Full Text: https://doi.org/10.1002/ajmg.a.30831]

  9. Westphal, V., Schottstadt, C., Marquardt, T., Freeze, H. H. Analysis of multiple mutations in the hALG6 gene in a patient with congenital disorder of glycosylation Ic. Molec. Genet. Metab. 70: 219-223, 2000. [PubMed: 10924277] [Full Text: https://doi.org/10.1006/mgme.2000.3017]


Contributors:
Cassandra L. Kniffin - updated : 5/19/2011
Hudson H. Freeze - updated : 2/17/2000
Hudson H. Freeze - reviewed : 2/17/2000
Victor A. McKusick - updated : 2/10/2000

Creation Date:
Victor A. McKusick : 10/15/1998

Edit History:
alopez : 05/15/2024
carol : 12/14/2023
carol : 10/06/2022
carol : 01/02/2020
carol : 06/05/2018
carol : 03/27/2017
alopez : 08/07/2015
terry : 9/14/2012
wwang : 6/8/2011
ckniffin : 5/19/2011
carol : 6/27/2007
carol : 6/26/2007
ckniffin : 6/26/2007
ckniffin : 6/22/2007
terry : 7/6/2004
carol : 3/1/2000
carol : 2/18/2000
carol : 2/17/2000
carol : 2/17/2000
terry : 2/10/2000
carol : 10/15/1998